EUVIMEDEUVIMED entdecken
Crossref

Implementation of CYP2C19 and CYP2D6 genotyping to guide antidepressant use in a large rural health system

Natasha J Petry, Joel Van Heukelom, April J Schultz, Kristen Jacobsen, Jordan F Baye, Sarah Mills, Debbie M Figueroa, Amanda Massmann

American Journal of Health-System Pharmacy · 2024

DOI: 10.1093/ajhp/zxae083 ↗

Kurz gefasst

Fachartikel in der Zeitschrift American Journal of Health-System Pharmacy, 2024. Verfasst von Natasha J Petry und 7 weiteren Autor:innen. Beteiligte Einrichtung: Sanford Imagenetics, Sanford Health, Sioux Falls, SD, and Department of Pharmacy Practice, North Dakota State University, Fargo, ND, USA. Hauptthemen laut MEDLINE: Cytochrome P-450 CYP2C19, Cytochrome P-450 CYP2D6, Antidepressive Agents. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 16 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

We describe the implementation and ongoing maintenance of CYP2C19 and CYP2D6 focused pharmacogenetic (PGx) testing to guide antidepressant and antianxiety medication prescriptions in a large rural, nonprofit health system. Summary Depression and anxiety are common psychiatric conditions. Sanford Health implemented PGx testing for metabolism of cytochrome P450 (CYP) isozymes 2C19 and 2D6 in 2014 to inform prescribing for multiple medications, including antidepressant and antianxiety therapies. As guidelines, genotype to phenotype translation, panel offerings, and other resources are updated, we adapt our approach. We make educational and informational materials available to providers and patients. Pharmacogenomic clinical pharmacists review PGx results with discrete values and provide guidance documentation in the electronic medical record. A robust clinical decision support system is in place to provide interruptive alerts, noninterruptive alerts, and genomic indicators. A referral-based interdisciplinary clinic is also available to provide in-depth education to patients regarding PGx results and implications. Additionally, partnering with our health plan has expanded access to PGx testing for patients with anxiety or depression.

Conclusion

The implementation and maintenance of Sanford Health’s PGx program to guide antidepressant and antianxiety medication use continues to evolve and requires a multipronged approach relying on both human and informatics-based resources.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cytochrome P-450 CYP2C19Cytochrome P-450 CYP2D6Antidepressive AgentsHumansGenotypePharmacogenomic TestingDepressionPharmacogeneticsDecision Support Systems, ClinicalElectronic Health RecordsRural Health ServicesAnxiety

Stichwörter der Autor:innen

CYP2C19CYP2D6anxietyclinical decision support systemsclinical implementationcytochrome P450 isozyme 2C19cytochrome P450 isozyme 2D6depressionpharmacogenetics

Substanzen

Cytochrome P-450 CYP2C19Cytochrome P-450 CYP2D6Antidepressive AgentsCYP2C19 protein, human

Autor:innen und Institutionen

  • Sanford Imagenetics, Sanford Health, Sioux Falls, SD, and Department of Pharmacy Practice, North Dakota State University, Fargo, ND, USA.
  • Sanford Imagenetics, Sanford Health, Sioux Falls, SD, and Department of Internal Medicine, University of South Dakota School of Medicine, Vermillion, SD, USA.
  • Sanford Imagenetics, Sanford Health, Sioux Falls, SD, USA.
  • Sanford Imagenetics, Sanford Health, Sioux Falls, SD, and South Dakota State University College of Pharmacy and Allied Health Professions, Brookings, SD, USA.
  • Sanford Medical Genetics Laboratory, Sanford Health, Sioux Falls, SD, and Department of Internal Medicine, University of South Dakota School of Medicine, Vermillion, SD, USA.

Zitieren

APA

Petry, N. J., Van Heukelom, J., Schultz, A. J., Jacobsen, K., Baye, J. F., Mills, S., Figueroa, D. M., & Massmann, A. (2024). Implementation of CYP2C19 and CYP2D6 genotyping to guide antidepressant use in a large rural health system. American Journal of Health-System Pharmacy. https://doi.org/10.1093/ajhp/zxae083

Vancouver

Petry NJ, Van Heukelom J, Schultz AJ, Jacobsen K, Baye JF, Mills S, et al. Implementation of CYP2C19 and CYP2D6 genotyping to guide antidepressant use in a large rural health system. American Journal of Health-System Pharmacy. 2024. doi:10.1093/ajhp/zxae083

BibTeX
@article{Petry2024,
  author = {Petry, Natasha J and Van Heukelom, Joel and Schultz, April J and Jacobsen, Kristen and Baye, Jordan F and Mills, Sarah and Figueroa, Debbie M and Massmann, Amanda},
  title = {Implementation of CYP2C19 and CYP2D6 genotyping to guide antidepressant use in a large rural health system},
  journal = {American Journal of Health-System Pharmacy},
  year = {2024},
  doi = {10.1093/ajhp/zxae083}
}
Kostenlos starten →